Altimmune (ALT) Short-Term Debt issuances (2012 - 2014)
Altimmune (ALT) posted quarterly Short-Term Debt issuances of -$1.1 million for Q1 2014, down 85593.88% year-over-year from N/an in Q1 2013, and down 200.0% quarter-over-quarter from $1.1 million in Q4 2013.
Analysis
Altimmune (ALT) Short-Term Debt issuances (2012 - 2014) Analysis & Trends
Altimmune (ALT) has reported Short-Term Debt issuances for 3 consecutive years, with -$1.1 million the latest figure, recorded in Q1 2014.
- In Q1 2014, Short-Term Debt issuances fell 85593.88% year-over-year to -$1.1 million; the TTM figure through Dec 2014 stood at -$1.1 million (down 357.24% YoY), while the FY2014 annual figure was -$1.1 million, down 357.24% from the prior year.
- Short-Term Debt issuances fell to -$1.1 million in Q1 2014 per ALT's latest filing, from $1.1 million in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $1.1 million in Q4 2013 and bottomed at -$1.2 million in Q3 2013.
- Historically, Short-Term Debt issuances has averaged -$50080.3 across 3 years, with a median of -$1274.0 in 2013.
- Annual changes were most pronounced in 2013 — Short-Term Debt issuances soared 793.87% — and 2014, when it sank 85593.88%.
- Altimmune's Short-Term Debt issuances stood at $122137.0 in 2012, then jumped by 793.87% to $1.1 million in 2013, then slumped by 200.0% to -$1.1 million in 2014.
- Business Quant data shows ALT's Short-Term Debt issuances at -$1.1 million in Q1 2014, $1.1 million in Q4 2013, and -$1.2 million in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2014 | -1.09 Mn |
| Dec 31, 2013 | 1.09 Mn |
| Sep 30, 2013 | -1.17 Mn |
| Jun 30, 2013 | -161,090.00 |
| Mar 31, 2013 | -1,274.00 |
| Dec 31, 2012 | 122,137.00 |
| Mar 31, 2012 | 857,808.00 |